Noile-Immune Biotech Income Statement

Financials in millions JPY. Fiscal year is January - December.

Millions JPY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Revenue	7	316	625	100	97
Revenue Growth (YoY)	-97.78%	-49.44%	525.00%	3.09%	-
Cost of Revenue	68	42	7	22	2
Gross Profit	-61	274	618	78	95
Selling, General & Admin	429	404	390	330	285
Research & Development	579	646	334	514	413
Operating Expenses	1,008	1,050	724	844	698
Operating Income	-1,069	-776	-106	-766	-603
Currency Exchange Gain (Loss)	-	-	5	-	-
Other Non Operating Income (Expenses)	107	-352	-283	-27	-2
EBT Excluding Unusual Items	-962	-1,128	-384	-793	-605
Gain (Loss) on Sale of Assets	-	-	-	-	-26
Pretax Income	-962	-1,128	-384	-793	-631
Income Tax Expense	2	2	2	2	5
Net Income	-964	-1,130	-386	-795	-636
Net Income to Common	-964	-1,130	-386	-795	-636
Shares Outstanding (Basic)	43	41	39	38	36
Shares Outstanding (Diluted)	43	41	39	38	36
Shares Change (YoY)	4.41%	5.87%	2.23%	7.89%	-
EPS (Basic)	-22.26	-27.25	-9.85	-20.75	-17.91
EPS (Diluted)	-22.26	-27.25	-9.85	-20.75	-17.91
Gross Margin	-	86.71%	98.88%	78.00%	97.94%
Operating Margin	-15271.43%	-245.57%	-16.96%	-766.00%	-621.65%
Profit Margin	-13771.43%	-357.60%	-61.76%	-795.00%	-655.67%
EBIT	-1,069	-776	-106	-766	-603
EBIT Margin	-	-245.57%	-16.96%	-	-

Updated Feb 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.